<DOC>
	<DOCNO>NCT01857908</DOCNO>
	<brief_summary>Adrenal androgen serum biomarkers interest may help guide abiraterone acetate treatment , particularly time progression . Biomarkers may also help identify pathway resistance abiraterone acetate treatment . The practical way approach question explore surrogate biomarkers prostate cancer include quantification pharmacodynamic endocrine biomarkers .</brief_summary>
	<brief_title>A Correlative Study Biomarkers Resistance Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone</brief_title>
	<detailed_description>Goals study include : - Explore circulate endocrine marker endocrine relate marker best potential predict clinical response abiraterone acetate CRPC patient - Explore utility microRNA , circulate DNA exosome analysis complement previous objective</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Signed write informed consent . Before study procedure perform , subject ( legally acceptable representative ) detail study describe , give write informed consent document read . If subject consent participate study , indicate consent sign date informed consent document presence study personnel Be suitable receive treatment abiraterone acetate prednisone Patients must histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell histology Patients may receive investigational agent dose escalation abiraterone acetate study participation Patient consent comply treatment abiraterone acetate direct physician Taking dose abiraterone acetate 1g daily lack compliance daily dose abiraterone acetate prednisone Patients receive spironolactone steroidogenic compound excess associate prednisone 5mg bid exclude due potential androgen receptor agonism</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Zytiga</keyword>
	<keyword>Correlative study</keyword>
	<keyword>Castrate Resistant Prostate Cancer</keyword>
	<keyword>Abiraterone Correlative study</keyword>
</DOC>